Jack Higgins
Hoofd Techniek/Wetenschap/O&O bij IMMUNOME, INC.
Vermogen: - $ op 31-05-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Clay Siegall | M | 63 |
MorphImmune, Inc.
 MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | 1 jaar |
| Max Rosett | M | 34 |
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | 2 jaar |
| Philip Wagenheim | M | 53 | 7 jaar | |
| Isaac Barchas | M | 56 | 1 jaar | |
| Matthew Robinson | M | 55 | 8 jaar | |
| Sandra Stoneman | F | 51 | 4 jaar | |
| Bruce Turner | M | 60 |
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | 1 jaar |
| Carol Schafer | F | 60 | - | |
| Jean-Jacques Bienaimé | M | 70 | 1 jaar | |
| James Boylan | M | 57 | 1 jaar | |
| Kinney Horn | M | 49 | - | |
| Bob Lechleider | M | 63 | 1 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Corleen Roche | F | 58 | 3 jaar | |
| Purnanand Sarma | M | 59 | 4 jaar | |
| Rapp Rapoport | M | 56 | 8 jaar | |
| John LaMattina | M | 74 | 6 jaar | |
| Richard Baron | M | 68 | 3 jaar | |
| Jason Kim | M | 49 |
Molecular Templates, Inc. /Old/
 Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | 7 jaar |
| Michael Lefenfeld | M | 43 | 6 jaar | |
| Steve Gullans | M | 71 |
Molecular Templates, Inc. /Old/
Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | - |
| Dennis Giesing | M | - | 2 jaar | |
| Timothy Sullivan | M | 53 |
Molecular Templates, Inc. /Old/
Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | 3 jaar |
| Erin Willert | M | - |
Molecular Templates, Inc. /Old/
Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | - |
| Jen-Sing Liu | M | - |
Molecular Templates, Inc. /Old/
Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | - |
| Michelle L. Lewis | F | - |
Molecular Templates, Inc. /Old/
Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | - |
| David J. Valacer | M | - |
Molecular Templates, Inc. /Old/
Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | - |
| Philip Roberts | M | - | 1 jaar | |
| Robert Lapetina | M | 49 | 3 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 28 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Jack Higgins
- Persoonlijk netwerk
